Pharmacological, clinical, and translational evidence for N,N-dimethyltryptamine, 5-methoxy-N,N-dimethyltryptamine, and zalsupindole: a systematic review
Publication date: 2 October 2026 Source: Progress in Neuro-Psychopharmacology and Biological Psychiatry, Volume 150 Author(s): Chad Collyer, Gia Han Le, Maryam Hassan, Sabrina Wong, Roger S. McIntyre
Pharmacological, clinical, and translational evidence for N,N-dimethyltryptamine, 5-methoxy-N,N-dimethyltryptamine, and zalsupindole: a systematic review. // Progress in Neuro-Psychopharmacology & Biological Psychiatry. – URL: https://www.sciencedirect.com/science/article/pii/S0278584626003647?dgcid=rss_sd_all
Pharmacological, clinical, and translational evidence for N,N-dimethyltryptamine, 5-methoxy-N,N-dimethyltryptamine, and zalsupindole: a systematic review. Progress in Neuro-Psychopharmacology & Biological Psychiatry. https://www.sciencedirect.com/science/article/pii/S0278584626003647?dgcid=rss_sd_all
“Pharmacological, clinical, and translational evidence for N,N-dimethyltryptamine, 5-methoxy-N,N-dimethyltryptamine, and zalsupindole: a systematic review.” Progress in Neuro-Psychopharmacology & Biological Psychiatry.
@article{article63041,
title = {Pharmacological, clinical, and translational evidence for N,N-dimethyltryptamine, 5-methoxy-N,N-dimethyltryptamine, and zalsupindole: a systematic review},
journal = {Progress in Neuro-Psychopharmacology \& Biological Psychiatry},
url = {https://www.sciencedirect.com/science/article/pii/S0278584626003647?dgcid=rss_sd_all}
}
Acta Pharmacologica Sinica, Published online: 16 November 2026; doi:10.1038/s41401-026-01953-z IRAK4 inhibitor DW18134 ameliorates diffuse large B-cell lymphoma in combination with ibrutinib and overcomes acquired resistance to ibrutinib
Acta Pharmacologica Sinica, Published online: 16 November 2026; doi:10.1038/s41401-026-01958-8 Artificial intelligence aids multi-omics data integration in cancer drug discovery and development: from targets to drug synergy
Nature Reviews Drug Discovery, Published online: 13 November 2026; doi:10.1038/d41573-026-00179-2 The NIH’s P. J. Brooks discusses the challenges and opportunities ahead for gene therapies and gene editing for diseases of no commercial interest.
Nature Reviews Drug Discovery, Published online: 13 November 2026; doi:10.1038/d41573-026-00181-8 Merck and Moderna’s intismeran autogene succeeded in a landmark melanoma trial, but the oncology community still has more questions than...